Epogen Sales Data

Rank 20 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Epogen U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 20 1.54% 1.12%
Q3 2013 20 (1) 3.80% 2.30%
Q2 2013 21 (2) 9.40% 3.39%
Q1 2013 23 (3) -2.08% -2.64%
Q4 2012 20 -2.27% -0.16%
Q3 2012 20 (2) -5.18% -3.04%
Q2 2012 22 (5) 13.33% 12.79%
Q1 2012 27 (7) -24.54% -17.04%
Q4 2011 20 (2) 4.67% 3.40%
Q3 2011 22 (2) -13.96% -18.41%
Q2 2011 20 (1) 3.32% 4.48%
Q1 2011 19

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
June 24, 2011FDA Modifies Dosing Recommendations for Erythropoiesis-Stimulating Agents
October 19, 2010FDA Advisers Back Anemia Drugs for Kidney Patients
October 19, 2010FDA Panel Backs Anemia Drugs For Kidney Disease
February 16, 2010FDA Tightens Controls on Anemia Drugs
December 3, 2008FDA Issues Questions and Answers on Medication Guides for Erythropoiesis-stimulating Agents (ESAs).
November 24, 2008Study Calls for Greater Scrutiny of 'Off-Label' Drug Use
September 26, 2008Anemia Drugs Linked to Stroke Study Deaths: FDA
Hide
(web1)